‘The positive 30-day results reaffirm my belief that a device that bioresorbs, or disappears, into the body after restoring blood flow may be the next logical step in the treatment of coronary disease,’ stated Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, holland, and principal investigator for the ABSORB trial. ‘The continuing positive results of the ABSORB trial and the medical benefits demonstrated to day by Abbott’s bioresorbable technology show promise a bioresorbable scaffold is coming to becoming a clinical reality and you will be another revolution in interventional cardiology.’ This second phase of the ABSORB medical trial enrolled 101 patients from 12 centers in Europe, Australia and New Zealand, and incorporates device enhancements made to improve deliverability and vessel support.Strokes greatly increased the hazard of death in both groupings . Main bleeding also improved the hazard of death in both organizations . Major vascular problems affected survival only in the TAVR group . Echocardiographic Results The early hemodynamic improvements which were seen with both medical substitute and TAVR were taken care of at 2 years, with no significant adjustments in valve areas or indicate gradients . Moderate or serious paravalvular aortic regurgitation was more common after TAVR than after surgical replacement at both 1 and 24 months . Among the 143 patients who underwent echocardiographic evaluation 24 months after TAVR, paravalvular aortic regurgitation remained unchanged in 46.2 percent of sufferers, was improved in 31.5 percent, and was worse in 22.4 percent .